Study of cholesterol-lowering effect and safety of simvaglisin on rabbit model of hypercholesterolemia.

Abstract

Using rabbit model of experimental hypercholesterolemia we showed that the hypocholesterolemic effect of simvaglisin, a complex preparation containing simvastatin and glycyrrhizic acid, in doses corresponding to 40, 66.5, and 100 mg/kg/day simvastatin is equal to the hypocholesterolemic effect of 200 mg/kg/day simvastatin alone. The total blood cholesterol decreased by 39, 36, 47, and 38% (p < 0.05), respectively, after 20-day course of the preparation. Myotoxicity of simvaglisin evaluated by serum creatine phosphokinase was lower than that of simvastatin. After 30-day treatment, this parameter was lower by 26, 24, and 29% (p < 0.05) than the corresponding parameter for simvastatin.

• Authors: Y I Ragino, V A Vavilin, N F Salakhutdinov, S I Makarova, E M Stakhneva, O G Safronova, Y P Nikitin, G A Tolstikov
• Journal: Bulletin of experimental biology and medicine (Bull Exp Biol Med) Vol. 145 Issue 3 Pg. 317-9 (Mar 2008) ISSN: 0007-4888 [Print] United States
• PMID: 19039932 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anticholesteremic Agents
• simvaglyzin
• Glycyrrhizic Acid
• Cholesterol
• Simvastatin
• Creatine Kinase

Topics

• Animals
• Anticholesteremic Agents (therapeutic use)
• Cholesterol (blood)
• Creatine Kinase (blood)
• Disease Models, Animal
• Glycyrrhizic Acid (therapeutic use)
• Hypercholesterolemia (drug therapy)
• Male
• Rabbits
• Simvastatin (therapeutic use)